ReNerve Secures CDSCO Approval for NervAlign Cuff in India

NEW DELHI — Australian biotechnology company ReNerve Limited (ASX: RNV) has officially secured marketing approval from the Central Drugs Standard Control Organization (CDSCO) to distribute its flagship NervAlign® Nerve Cuff across India.

Announced by corporate authorities, the regulatory milestone clears the path for the bioabsorbable medical device to enter one of the world's fastest-growing healthcare markets. The approval allows ReNerve to expand its commercial footprint beyond North America and Southeast Asia, offering advanced peripheral nerve repair solutions to surgical centers throughout India.

Expanding Access to Advanced Peripheral Nerve Repair

The NervAlign® Nerve Cuff is a pliable, tissue-compatible protective wrap designed to support and safeguard injured peripheral nerves following trauma or surgical intervention. By creating an optimized microenvironment for nerve regeneration, the bioabsorbable device naturally integrates and dissolves over time, leaving native tissue intact.

According to corporate filings and regulatory documentation:

• Regulatory Clearance: The CDSCO green light validates the product's clinical evaluation data, confirming safety and efficacy profiles for diverse patient populations.

• Clinical Efficacy: Clinical studies highlight significant reductions in post-surgical patient pain scores when utilizing the protective nerve cuff compared to standard surgical care.

• Strategic Growth: India joins an expanding international portfolio that includes approvals in the United States, Malaysia, the Philippines, Thailand, Hong Kong, and New Zealand.

Official Sources Section

• Central Drugs Standard Control Organization (CDSCO) Regulatory Filings: Official medical device market registration and import authorization records.

• ReNerve Limited ASX Disclosures: Corporate announcements, regulatory updates, and commercialization strategies under ticker RNV.AX.

Quote Section

According to official statements released by ReNerve corporate management:

"Securing CDSCO approval in India represents a major strategic milestone for our international expansion, providing access to a rapidly scaling healthcare sector with a high clinical demand for advanced surgical solutions."

Why It Matters

For surgical specialists, healthcare providers, and patients across India, the introduction of the NervAlign® Nerve Cuff offers an advanced clinical tool for managing complex peripheral nerve injuries resulting from trauma, accidents, or chronic conditions like diabetes. For investors, the regulatory clearance broadens ReNerve's addressable market within the high-growth Asia-Pacific medical technology sector.

Key Facts at a Glance

• Company: ReNerve Limited (ASX: RNV).

• Product: NervAlign® Nerve Cuff (bioabsorbable peripheral nerve protection wrap).

• Regulatory Body: Central Drugs Standard Control Organization (CDSCO), India.

• Clinical Benefit: Designed to protect surgical nerve repairs and facilitate natural regeneration while reducing post-operative complications.

FAQ Section

What is the NervAlign® Nerve Cuff?

It is a bioabsorbable medical device wrapped around injured peripheral nerves during surgery to protect the repair site and promote natural nerve regeneration.

What does the CDSCO approval mean for ReNerve?

The regulatory approval grants ReNerve legal permission to market and distribute the NervAlign® Nerve Cuff to hospitals and surgical centers across India.

Where else is the NervAlign® Nerve Cuff approved for use?

In addition to India, the device holds regulatory clearances in the United States, Malaysia, the Philippines, Thailand, Hong Kong, and New Zealand.

How does the device degrade in the body?

The nerve cuff is constructed from tissue-compatible materials that are naturally bio-absorbed over time, leaving the healed nerve in its native state.

Source: CDSCO, ReNerve ASX Disclosures, Market Index